Answers are grounded in this paper and cite their sources.
In vitro and in vivo data have demonstrated that virus-mediated p53 gene transfer can induce active cell death and lung tumor regression. In contrast, the therapeutic potential of bax, another apoptosis-inducing gene, has not been described. We compared p53 and bax cytotoxic effects by transient transfection of an average of 25 ± 5% of the H-322 and H-358 bronchioloalveolar carcinoma cell lines in vitro. Under these conditions, bax expression killed 70 to 90% of the transfected cells whereas p53 killed only 40% of them. The killing activity of both genes involved apoptosis, as shown by TUNEL staining. Surprisingly, BrdU incorporation indicated that the cells that did resist Bax toxicity were blocked in the pre-S phase of the cell cycle, a result expected for p53 only. In vivo, repeated injections of naked DNA encoding Bax or p53 inhibited the growth of 4-mm preestablished H-322 tumors in nude mice. Growth retardation only, and not inhibition, was observed in H-358, a poorly transfectable and rapidly growing tumor. These results indicate that Bax and p53 share a similar, strong antitumor activity in vivo, even if the former is a more potent inducer of apoptosis in vitro. On the basis of the widespread use of wild-type p53 for gene therapy of cancer, we compared the cytotoxic effect of bax and p53 on two lung cancer cell lines. Our results showed that bax was a stronger inductor of apoptosis than was p53 in vitro. In vivo, both genes shared a strong antitumor activity, inducing tumor growth inhibition in preestablished NSCLCC tumors. This suggested that bax is like p53, a good candidate for gene therapy applications.
No takes yet. Share an insight, caveat, or question.
Coll et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: